Rfviii
Severe Hemophilia A
Chulalongkorn UniversityPhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Severe Hemophilia A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX AryoGen Pharmed Co. | Phase 4 | BBB |
Emicizumab Chulalongkorn University | Phase 4 | BBB |
Human-Cl Rhfviii Octapharma | Phase 3 | BBB |
Rfviiifc Bioverativ Therapeutics Inc. | Phase 3 | BB |
Alphanate Sd/Ht Grifols Biologicals, LLC | Phase 4 | BB |
View all 17 →
Same molecule, other indications
Rfviii is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →